Author

Arnold Bolomsky

National Institutes of HealthORCID 0000-0002-1585-5429Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. O. Parsons· 1 shared Aaliyah BattleiD· 1 shared Alina MalyutinaiD· 1 shared André C. MülleriD· 1 shared Björn HäupliD· 1 shared Callie K. VanWinkleiD· 1 shared Caroline Akemi HeckmaniD· 1 shared Elizabeth HilliD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. O. Parsons

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyBlood Cancer DiscoveryPeer-reviewedAug 31, 2026

Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation

Lin Zhang, Arnold Bolomsky, Omar S. Al‐Odat…·Ryan M. Young

This study identifies phosphorylation as a mechanism protecting oncogenic RAS from LZTR1-mediated degradation, with implications for targeting RAS stability in hematologic cancers.

DOI 10.1158/2643-3230.bcd-26-0028

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 26, 2024

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma

Alina Malyutina, Philipp Sergeev, Julia Huber…·Caroline Akemi Heckman

This study identifies molecular mechanisms of carfilzomib resistance in multiple myeloma using multi-omics data from cell lines and patient samples, revealing potential drug combinations to overcome resistance.

2 citations

humanproteomics

𝕏 PostBluesky